Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 14,375 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $44.47, for a total transaction of $639,256.25. Following the sale, the insider now directly owns 27,786 shares in the company, valued at approximately $1,235,643.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Dana Pizzuti also recently made the following trade(s):
- On Wednesday, March 20th, Dana Pizzuti sold 15,089 shares of Crinetics Pharmaceuticals stock. The shares were sold at an average price of $44.06, for a total transaction of $664,821.34.
Crinetics Pharmaceuticals Trading Up 1.2 %
Shares of CRNX stock opened at $44.01 on Thursday. The firm has a fifty day moving average price of $42.26 and a 200 day moving average price of $35.95. The company has a market cap of $3.06 billion, a P/E ratio of -11.89 and a beta of 0.63. Crinetics Pharmaceuticals, Inc. has a 12 month low of $15.76 and a 12 month high of $49.58.
Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.01). Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative return on equity of 52.93%. During the same quarter in the previous year, the firm earned ($0.84) earnings per share. The firm's revenue was down 100.0% compared to the same quarter last year. On average, equities analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.34 EPS for the current year.
Institutional Investors Weigh In On Crinetics Pharmaceuticals
š± This phenomenon is smashing regular market gains
From MillPub | Ad
Thanks to a little-known āPathfinderā trading phenomenonā¦
Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading.
At every single market open.
Click here to save your seat and join the next LIVE workshop!
A number of institutional investors and hedge funds have recently bought and sold shares of CRNX. Tower Research Capital LLC TRC lifted its position in Crinetics Pharmaceuticals by 109.9% in the first quarter. Tower Research Capital LLC TRC now owns 1,927 shares of the company's stock valued at $31,000 after acquiring an additional 1,009 shares during the last quarter. Quarry LP purchased a new stake in shares of Crinetics Pharmaceuticals in the fourth quarter valued at about $36,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Crinetics Pharmaceuticals by 98.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,403 shares of the company's stock valued at $42,000 after buying an additional 695 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Crinetics Pharmaceuticals by 382.4% in the second quarter. Osaic Holdings Inc. now owns 2,412 shares of the company's stock valued at $43,000 after buying an additional 1,912 shares during the last quarter. Finally, AJOVista LLC purchased a new stake in shares of Crinetics Pharmaceuticals in the fourth quarter valued at about $58,000. 98.51% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
CRNX has been the subject of several research reports. Cantor Fitzgerald lifted their target price on shares of Crinetics Pharmaceuticals from $50.00 to $65.00 and gave the company an "overweight" rating in a report on Monday, March 4th. JMP Securities reiterated a "market outperform" rating and issued a $80.00 target price on shares of Crinetics Pharmaceuticals in a report on Thursday, March 28th. Citigroup initiated coverage on shares of Crinetics Pharmaceuticals in a report on Wednesday, March 6th. They issued a "buy" rating and a $68.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Crinetics Pharmaceuticals in a report on Tuesday, March 19th. Finally, Jonestrading boosted their price target on shares of Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday, March 20th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $54.17.
Check Out Our Latest Report on CRNX
About Crinetics Pharmaceuticals
(
Get Free Report)
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
